Results 71 to 80 of about 23,600 (247)

Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. [PDF]

, 2001
Ligation of the cell-surface Fas molecule by its ligand (Fas-L) or agonistic anti-Fas monoclonal antibodies results in the cleavage and activation of the cysteine protease procaspase 8 followed by the activation of procaspase 3 and by apoptosis.
Folarin, NI, Ganeshaguru, K, Hoffbrand, AV, Jones, DT, Lowdell, MW, Mehta, AB, Prentice, HG, Virchis, AE, Wickremasinghe, RG   +8 more
core  

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Chronic Lymphocytic Leukemia in Elderly Patients: Own Experience

Львівський клінічний вісник, 2017
Introduction. The annual incidence rate of chronic lymphocytic leukemia (CLL) in Europe is 1­4 per 100 000 population. The disease is more common in older patients.
Vyhovska O., Vyhovska Ya. , Shalay O. , Lukavetskyy L. , Voytsitskyy V. , Shevchenko L., Barilka V. , Maslyak Z.   +7 more
doaj   +1 more source

Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report [PDF]

, 2008
INTRODUCTION: Treatment of chronic lymphocytic leukemia of the B-cell-lineage is strongly based upon clinical staging because of the heterogeneous clinical course of this disease.
Isrid Sturm, Joachim Oertel, Stephan Oertel, Jörg Westermann, Antonio Pezzutto, G Dighiero, U Winkler, A Gozzetti, JD Hainsworth, D Huhn, S Srock, SM O'Brien   +11 more
core   +3 more sources

Redox-Responsive Heparin–Chlorambucil Conjugate Polymeric Prodrug for Improved Anti-Tumor Activity

Polymers, 2019
Polymeric prodrug-based delivery systems have been extensively studied to find a better solution for the limitations of a single drug and to improve the therapeutic and pharmacodynamics properties of chemotherapeutic agents, which can lead to efficient ...
Abegaz Andrgie, Y. Birhan, T. Mekonnen, Endiries Yibru Hanurry, H. F. Darge, R. Lee, Hsiao-Ying Chou, Hsieh-Chih Tsai   +7 more
semanticscholar   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. [PDF]

PLoS ONE, 2013
Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse ...
Nelly Mezzaroba, Sonia Zorzet, Erika Secco, Stefania Biffi, Claudio Tripodo, Marco Calvaruso, Ramiro Mendoza-Maldonado, Sara Capolla, Marilena Granzotto, Ruben Spretz, Gustavo Larsen, Sandra Noriega, Marianna Lucafò, Eduardo Mansilla, Chiara Garrovo, Gustavo H Marín, Gabriele Baj, Valter Gattei, Gabriele Pozzato, Luis Núñez, Paolo Macor   +20 more
doaj   +1 more source

Clinical management and outcomes for 51 Pugs reportedly diagnosed with protein‐losing enteropathy using VetCompass primary care veterinary data

Journal of Small Animal Practice, EarlyView.
Objectives To report the clinicopathological findings, treatment and outcomes of Pugs diagnosed with protein‐losing enteropathy using VetCompass primary care clinical data in the UK and to determine if referral or any specific treatments for protein‐losing enteropathy were associated with outcome. Materials and Methods Retrospective VetCompass study of
A. Kathrani, D. C. Brodbelt, D. B. Church, D. G. O’Neill   +3 more
wiley   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.
What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

Combined Application of CAR-T Cells and Chlorambucil for CLL Treatment: Insights from Nonlinear Dynamical Systems and Model-Based Design for Dose Finding

Hemato
Background: This work presents a mechanistic nonlinear model, formulated as a system of first-order Ordinary Differential Equations, to investigate the dynamics of Chronic Lymphocytic Leukemia (CLL) under combined chemoimmunotherapy using CAR-T cells and
Paul A. Valle, Luis N. Coria, Yolocuauhtli Salazar, Corina Plata, Luis A. Ramirez   +4 more
doaj   +1 more source